SYMBIOTEC PHARMALAB LTD is a listed company listed on NSE. The annual-report business brief for this company has not been generated yet; the numbers below are as filed.
| ₹ crore · consolidated |
|---|
| Revenue |
| EBITDA (ex other income) |
| margin % |
| Owners' profit |
| EPS, as reported (₹) |
| ROE % · ROCE % |
| Debt / equity (x) |
| Cash from operations |
| Capex |
| ₹ crore |
|---|
| Revenue |
| Profit before tax |
| Net profit |
| EPS (₹) |
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 11 Sept 2026 · Board meeting on Sep 21 to consider Q1 FY27 results | board shareholder meetings | low | — | — |
| 11 Sept 2026 · Promoter group pledges 5.44 percent shares to secure debentures | ownership changes | high | — | — |
| 3 Sept 2026 · Symbiotec Pharmalab submits insider trading fair disclosure code to exchanges | compliance | minimal | — | — |
| 2 Sept 2026 · Mirae Asset MF raises stake in Symbiotec Pharmalab to 6.22 percent via open market | ownership changes | medium | — | — |
| 1 Sept 2026 · Trading window closure for Q1 FY27 results | compliance | minimal | — | — |
| 1 Sept 2026 · Fair Disclosure Code submitted to BSE and NSE under SEBI insider trading rules | compliance | minimal | — | — |
| 1 Sept 2026 · Symbiotec Pharmalab names KMPs authorized to decide on material event disclosures | compliance | minimal | — | — |
| 1 Sept 2026 · Symbiotec Pharmalab shares to begin trading on BSE from Sept 1, 2026 | capital market events | high | — | — |
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions | an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates |
| MarketPing publishes no forecasts — your own model lives on the Models page |
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
